Gui-Lian Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gui-Lian Xu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Feng Xu
Department of Immunology, Basic Medicine College Army Medical University Chongqing China
5 shared publicationsGui-Qing Li
Department of Immunology, Army Medical University (Third Military Medical University), Chongqing 400038, China
4 shared publicationsQuan-You Zheng
Department of Urology, 958th Hospital of PLA, Army Medical University, Chongqing, China
4 shared publicationsShun Wu
Department of Nephrology, Huaihai Hospital affiliated with Xuzhou Medical University, Xuzhou 221004, China
4 shared publicationsJian Chen
Department of Immunology, Basic Medicine College Army Medical University Chongqing China
3 shared publicationsMing Tang
Urinary Nephropathy Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publications
Latest Publications
- Open Access
- 28 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Environmental toxicant ochratoxin A induces psoriasis based on network toxicology machine learning and molecular docking analyses
Psoriasis is a chronic skin disease influenced by genetic susceptibility and environmental factors. Ochratoxin A (OTA) is a ubiquitous foodborne mycotoxin known for its immunotoxicity, however, its specific role in psoriasis pathogenesis remains underexplored. This study implemented an integrated systems biology framework that combined network toxicology, machine learning, and molecular dynamics to elucidate the mechanisms of OTA-induced psoriasis. By intersecting OTA-associated targets with psoriasis-related genes, we identified 242 potential targets that were significantly enriched in the IL-17 and TNF signaling pathways. We utilized a weighted gene co-expression network analysis combined with nine machine learning algorithms to identify five hub genes based on their high feature importance and diagnostic robustness: PNP, LCN2, HSPE1, TYMP, and CXCR2, with an area under the curve of 0.988 in the training set and 1.00 in the external validation. These hub genes positively correlated with activated dendritic cells and eosinophils, suggesting that they mediate a pro-inflammatory microenvironment. Molecular docking and dynamics simulations demonstrated stable binding affinities (up to − 8.8 kcal/mol) between OTA and the corresponding proteins. Our findings establish a mechanistic link whereby OTA directly interacts with key regulatory proteins to drive immune dysregulation, providing novel biomarkers and a theoretical basis for managing OTA-induced psoriasis.
- 28 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessEnvironmental toxicant ochratoxin A induces psoriasis based on network toxicology machine learning and molecular docking analyses
Psoriasis is a chronic skin disease influenced by genetic susceptibility and environmental factors. Ochratoxin A (OTA) is a ubiquitous foodborne mycotoxin known for its immunotoxicity, however, its specific role in psoriasis pathogenesis remains underexplored. This study implemented an integrated systems biology framework that combined network toxicology, machine learning, and molecular dynamics to elucidate the mechanisms of OTA-induced psoriasis. By intersecting OTA-associated targets with psoriasis-related genes, we identified 242 potential targets that were significantly enriched in the IL-17 and TNF signaling pathways. We utilized a weighted gene co-expression network analysis combined with nine machine learning algorithms to identify five hub genes based on their high feature importance and diagnostic robustness: PNP, LCN2, HSPE1, TYMP, and CXCR2, with an area under the curve of 0.988 in the training set and 1.00 in the external validation. These hub genes positively correlated with activated dendritic cells and eosinophils, suggesting that they mediate a pro-inflammatory microenvironment. Molecular docking and dynamics simulations demonstrated stable binding affinities (up to − 8.8 kcal/mol) between OTA and the corresponding proteins. Our findings establish a mechanistic link whereby OTA directly interacts with key regulatory proteins to drive immune dysregulation, providing novel biomarkers and a theoretical basis for managing OTA-induced psoriasis.
- Open Access
- 6 August 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (15) , e70774
TNFSF14‐HVEM/LTβR Exacerbates Keratinocyte Abnormalities and IMQ‐Induced Psoriatic Skin Inflammation via Activating NF‐κB/TWIST1 Signalling Pathway
Psoriasis (PS) is a chronic autoimmune skin disease that poses a serious threat to over 100 million patients worldwide. An increasing number of studies have indicated that keratinocytes (KCs) play an essential role in the inflammatory progression of PS. The present study found that tumour necrosis factor superfamily member 14 (TNFSF14) and its two receptors were up‐regulated in IMQ‐primed KCs and psoriatic skin sections. It also revealed that blocking TNFSF14 signalling (via gene knockout or injections) with its receptors' soluble fusion proteins lymphotoxin beta receptor (LTβR)–immunoglobulin G Fc domain (LTβR‐IgGFc) and herpesvirus entry mediator–IgGFc (HVEM‐IgGFc) significantly alleviated imiquimod (IMQ)‐induced psoriatic skin inflammation by attenuating epidermal hyperplasia, decreasing cellular proliferation, keratinisation, apoptosis, and inflammatory response. Accordingly, direct stimulation with recombinant TNFSF14 markedly enhanced KC abnormalities as evidenced by aggravated cell proliferation and keratinisation, increased cellular apoptosis, and up‐regulated inflammatory cytokine expression. Mechanistic studies demonstrated that TNFSF14 mediates KC abnormalities via the nuclear factor‐kappa B (NF‐κB)/TWIST1 pathway. Taken together, our study findings indicate that TNFSF14‐HVEM/LTβR promotes KC dysfunction and IMQ‐induced psoriatic skin inflammation via enhancing NF‐κB/TWIST1 signalling and suggest that TNFSF14 is a promising therapeutic strategy for the clinical treatment of PS.
- 6 August 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (15) , e70774
Open AccessTNFSF14‐HVEM/LTβR Exacerbates Keratinocyte Abnormalities and IMQ‐Induced Psoriatic Skin Inflammation via Activating NF‐κB/TWIST1 Signalling Pathway
Psoriasis (PS) is a chronic autoimmune skin disease that poses a serious threat to over 100 million patients worldwide. An increasing number of studies have indicated that keratinocytes (KCs) play an essential role in the inflammatory progression of PS. The present study found that tumour necrosis factor superfamily member 14 (TNFSF14) and its two receptors were up‐regulated in IMQ‐primed KCs and psoriatic skin sections. It also revealed that blocking TNFSF14 signalling (via gene knockout or injections) with its receptors' soluble fusion proteins lymphotoxin beta receptor (LTβR)–immunoglobulin G Fc domain (LTβR‐IgGFc) and herpesvirus entry mediator–IgGFc (HVEM‐IgGFc) significantly alleviated imiquimod (IMQ)‐induced psoriatic skin inflammation by attenuating epidermal hyperplasia, decreasing cellular proliferation, keratinisation, apoptosis, and inflammatory response. Accordingly, direct stimulation with recombinant TNFSF14 markedly enhanced KC abnormalities as evidenced by aggravated cell proliferation and keratinisation, increased cellular apoptosis, and up‐regulated inflammatory cytokine expression. Mechanistic studies demonstrated that TNFSF14 mediates KC abnormalities via the nuclear factor‐kappa B (NF‐κB)/TWIST1 pathway. Taken together, our study findings indicate that TNFSF14‐HVEM/LTβR promotes KC dysfunction and IMQ‐induced psoriatic skin inflammation via enhancing NF‐κB/TWIST1 signalling and suggest that TNFSF14 is a promising therapeutic strategy for the clinical treatment of PS.
- 28 May 2024
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 42 (9) , 848-859
Human mesenchymal stromal cells ameliorate cisplatin-induced acute and chronic kidney injury via TSG-6
Cisplatin is widely employed in tumor chemotherapy, but nephrotoxicity is an unavoidable side effect of cisplatin. Several studies have demonstrated that mesenchymal stromal cells (MSCs) ameliorate cisplatin-induced kidney injury, but the underlying mechanisms are unknown. In this study, the cisplatin-induced kidney injury mouse model was established by subjecting a single intraperitoneal injection with cisplatin. One hour before cisplatin injection, the mice received human bone marrow MSCs (hBM-MSCs) with or without siRNA-transfection, recombinant human tumor necrosis factor (TNF)-α-stimulated gene/protein 6 (rhTSG-6), or PBS through tail vein. In addition, cisplatin-stimulated HK-2 cells were treated with hBM-MSCs or rhTSG-6. hBM-MSCs treatment remarkably ameliorated cisplatin-induced acute and chronic kidney injury, as evidenced by significant reductions in serum creatinine (Scr), blood urea nitrogen (BUN), tubular injury, collagen deposition, α-smooth muscle actin accumulation, as well as inflammatory responses, and by remarkable increased anti-inflammatory factor expression and Treg cells infiltration in renal tissues. Furthermore, we found that only a few hBM-MSCs engrafted into damaged kidney and that the level of human TSG-6 in serum of mice increased significantly following hBM-MSCs administration. Moreover, hBM-MSCs significantly increased the viability of damaged HK-2 cells and decreased the levels of inflammatory cytokines in the culture supernatant. However, knockdown of TSG-6 gene in hBM-MSCs significantly attenuated their beneficial effects in vivo and in vitro. On the contrary, treated with rhTSG-6 achieved similar beneficial effects of hBM-MSCs. Our results indicate that systemic administration of hBM-MSCs alleviate cisplatin-induced acute and chronic kidney injury in part by paracrine TSG-6 secretion.
- 28 May 2024
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 42 (9) , 848-859
Human mesenchymal stromal cells ameliorate cisplatin-induced acute and chronic kidney injury via TSG-6
Cisplatin is widely employed in tumor chemotherapy, but nephrotoxicity is an unavoidable side effect of cisplatin. Several studies have demonstrated that mesenchymal stromal cells (MSCs) ameliorate cisplatin-induced kidney injury, but the underlying mechanisms are unknown. In this study, the cisplatin-induced kidney injury mouse model was established by subjecting a single intraperitoneal injection with cisplatin. One hour before cisplatin injection, the mice received human bone marrow MSCs (hBM-MSCs) with or without siRNA-transfection, recombinant human tumor necrosis factor (TNF)-α-stimulated gene/protein 6 (rhTSG-6), or PBS through tail vein. In addition, cisplatin-stimulated HK-2 cells were treated with hBM-MSCs or rhTSG-6. hBM-MSCs treatment remarkably ameliorated cisplatin-induced acute and chronic kidney injury, as evidenced by significant reductions in serum creatinine (Scr), blood urea nitrogen (BUN), tubular injury, collagen deposition, α-smooth muscle actin accumulation, as well as inflammatory responses, and by remarkable increased anti-inflammatory factor expression and Treg cells infiltration in renal tissues. Furthermore, we found that only a few hBM-MSCs engrafted into damaged kidney and that the level of human TSG-6 in serum of mice increased significantly following hBM-MSCs administration. Moreover, hBM-MSCs significantly increased the viability of damaged HK-2 cells and decreased the levels of inflammatory cytokines in the culture supernatant. However, knockdown of TSG-6 gene in hBM-MSCs significantly attenuated their beneficial effects in vivo and in vitro. On the contrary, treated with rhTSG-6 achieved similar beneficial effects of hBM-MSCs. Our results indicate that systemic administration of hBM-MSCs alleviate cisplatin-induced acute and chronic kidney injury in part by paracrine TSG-6 secretion.
- 1 December 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 89, 106999
LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis
- 1 December 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 89, 106999
LIGHT deficiency aggravates cisplatin-induced acute kidney injury by upregulating mitochondrial apoptosis
- Open Access
- 1 October 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 130, 110468
Fibrinogen-like protein 2 deficiency aggravates renal fibrosis by facilitating macrophage polarization
- 1 October 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 130, 110468
Open AccessFibrinogen-like protein 2 deficiency aggravates renal fibrosis by facilitating macrophage polarization
- 1 August 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 85, 106692
Complement component 3 prevents imiquimod-induced psoriatic skin inflammation by inhibiting apoptosis in mice
- 1 August 2020
- Published by Elsevier in International Immunopharmacology
- Vol. 85, 106692
Complement component 3 prevents imiquimod-induced psoriatic skin inflammation by inhibiting apoptosis in mice
- Open Access
- 18 June 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (8) , 10590-10604
C5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells
Psoriasis is a chronic relapsing inflammatory skin disease, affecting up to 3% of the global population. Accumulating evidence suggests that the complement system is involved in its pathogenesis. Our previous study revealed that the C5a/C5aR1 pathway is crucial for disease development. However, the underlying mechanisms remain largely unknown. To explore potential mechanisms, psoriatic skin lesions and histological changes were assessed following imiquimod (IMQ) cream treatment. Inflammatory cytokine expression was tested by real‐time RT‐PCR. Immunohistochemistry and flow cytometry were used to identify inflammatory cell infiltration and interleukin (IL‐17A) IL‐17A expression. A C5aR1 antagonist (C5aR1a) and PI3K inhibitor (wortmannin) were used for blocking experiments (both in vivo and in vitro) to explore the mechanism. C5a/C5aR1‐pathway inhibition significantly attenuated psoriasis‐like skin lesions with decreased epidermal hyperplasia, downregulated type 17‐related inflammatory gene expression, and reduced IL‐17A‐producing γδ‐T cell responses. Mechanistically, C5a/C5aR1 promoted the latter phenotype via PI3K‐Akt signaling. Consistently, C5aR1 deficiency clearly ameliorated IMQ‐induced chronic psoriasiform dermatitis, with a significant decrease in IL‐17A expression. Finally, blocking C5aR1 signaling further decreased psoriasiform skin inflammation in IL‐17‐deficient mice. Results suggest that C5a/C5aR1 mediates experimental psoriasis and skin inflammation by upregulating IL‐17A expression from γδ‐T cells. Blocking C5a/C5aR1/IL‐17A axis is expected to be a promising strategy for psoriasis treatment.
- 18 June 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (8) , 10590-10604
Open AccessC5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells
Psoriasis is a chronic relapsing inflammatory skin disease, affecting up to 3% of the global population. Accumulating evidence suggests that the complement system is involved in its pathogenesis. Our previous study revealed that the C5a/C5aR1 pathway is crucial for disease development. However, the underlying mechanisms remain largely unknown. To explore potential mechanisms, psoriatic skin lesions and histological changes were assessed following imiquimod (IMQ) cream treatment. Inflammatory cytokine expression was tested by real‐time RT‐PCR. Immunohistochemistry and flow cytometry were used to identify inflammatory cell infiltration and interleukin (IL‐17A) IL‐17A expression. A C5aR1 antagonist (C5aR1a) and PI3K inhibitor (wortmannin) were used for blocking experiments (both in vivo and in vitro) to explore the mechanism. C5a/C5aR1‐pathway inhibition significantly attenuated psoriasis‐like skin lesions with decreased epidermal hyperplasia, downregulated type 17‐related inflammatory gene expression, and reduced IL‐17A‐producing γδ‐T cell responses. Mechanistically, C5a/C5aR1 promoted the latter phenotype via PI3K‐Akt signaling. Consistently, C5aR1 deficiency clearly ameliorated IMQ‐induced chronic psoriasiform dermatitis, with a significant decrease in IL‐17A expression. Finally, blocking C5aR1 signaling further decreased psoriasiform skin inflammation in IL‐17‐deficient mice. Results suggest that C5a/C5aR1 mediates experimental psoriasis and skin inflammation by upregulating IL‐17A expression from γδ‐T cells. Blocking C5a/C5aR1/IL‐17A axis is expected to be a promising strategy for psoriasis treatment.
- Open Access
- 22 May 2018
- Published by Springer Nature in Cell Death & Disease
- Vol. 9 (6) , 1-12
Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression
Renal fibrosis is the final manifestation of various chronic kidney diseases, and no effective therapy is available to prevent or reverse it. Celastrol, a triterpene that derived from traditional Chinese medicine, is a known potent anti-fibrotic agent. However, the underlying mechanisms of action of celastrol on renal fibrosis remain unknown. In this study, we found that celastrol treatment remarkably attenuated unilateral ureteral obstruction (UUO)-induced mouse renal fibrosis. This was evidenced by the significant reduction in tubular injury; collagen deposition; accumulation of fibronectin, collagen I, and α-smooth muscle actin; and the expression levels of pro-fibrotic factors Vim, Cola1, and TGF-β1 mRNA, as well as inflammatory responses. Celastrol showed similar effects in a folic acid-induced mouse renal fibrosis model. Furthermore, celastrol potentiated the expression of the anti-fibrotic factor cannabinoid receptor 2 (CB2R) in established mouse fibrotic kidney tissues and transforming growth factor β1 (TGF-β1)-stimulated human kidney 2 (HK-2) cells. In addition, the CB2R antagonist (SR144528) abolished celastrol-mediated beneficial effects on renal fibrosis. Moreover, UUO- or TGF-β1-induced activation of the pro-fibrotic factor SMAD family member 3 (Smad3) was markedly inhibited by celastrol. Inhibition of Smad3 activation by an inhibitor (SIS3) markedly reduced TGF-β1-induced downregulation of CB2R expression. In conclusion, our study provides the first direct evidence that celastrol significantly alleviated renal fibrosis, by contributing to the upregulation of CB2R expression through inhibiting Smad3 signaling pathway activation. Therefore, celastrol could be a potential drug for treating patients with renal fibrosis.
- 22 May 2018
- Published by Springer Nature in Cell Death & Disease
- Vol. 9 (6) , 1-12
Open AccessCelastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression
Renal fibrosis is the final manifestation of various chronic kidney diseases, and no effective therapy is available to prevent or reverse it. Celastrol, a triterpene that derived from traditional Chinese medicine, is a known potent anti-fibrotic agent. However, the underlying mechanisms of action of celastrol on renal fibrosis remain unknown. In this study, we found that celastrol treatment remarkably attenuated unilateral ureteral obstruction (UUO)-induced mouse renal fibrosis. This was evidenced by the significant reduction in tubular injury; collagen deposition; accumulation of fibronectin, collagen I, and α-smooth muscle actin; and the expression levels of pro-fibrotic factors Vim, Cola1, and TGF-β1 mRNA, as well as inflammatory responses. Celastrol showed similar effects in a folic acid-induced mouse renal fibrosis model. Furthermore, celastrol potentiated the expression of the anti-fibrotic factor cannabinoid receptor 2 (CB2R) in established mouse fibrotic kidney tissues and transforming growth factor β1 (TGF-β1)-stimulated human kidney 2 (HK-2) cells. In addition, the CB2R antagonist (SR144528) abolished celastrol-mediated beneficial effects on renal fibrosis. Moreover, UUO- or TGF-β1-induced activation of the pro-fibrotic factor SMAD family member 3 (Smad3) was markedly inhibited by celastrol. Inhibition of Smad3 activation by an inhibitor (SIS3) markedly reduced TGF-β1-induced downregulation of CB2R expression. In conclusion, our study provides the first direct evidence that celastrol significantly alleviated renal fibrosis, by contributing to the upregulation of CB2R expression through inhibiting Smad3 signaling pathway activation. Therefore, celastrol could be a potential drug for treating patients with renal fibrosis.
- 1 January 2018
- Published by Elsevier in Cancer Letters
- Vol. 412, 30-36
Complement C5a/C5aR pathway potentiates the pathogenesis of gastric cancer by down-regulating p21 expression
- 1 January 2018
- Published by Elsevier in Cancer Letters
- Vol. 412, 30-36
Complement C5a/C5aR pathway potentiates the pathogenesis of gastric cancer by down-regulating p21 expression